These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6126746)

  • 1. Site of action of thioridazine.
    Borison RL; Blowers AJ
    Lancet; 1982 Oct; 2(8303):883. PubMed ID: 6126746
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect?
    Costall B; Naylor RJ
    Psychopharmacologia; 1973; 32(2):161-70. PubMed ID: 4796282
    [No Abstract]   [Full Text] [Related]  

  • 3. [Schizophrenia and dopamine (author's transl)].
    Toru M
    Tanpakushitsu Kakusan Koso; 1978; 23(4):303-16. PubMed ID: 26107
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular dynamics and density functional studies on the metabolic selectivity of antipsychotic thioridazine by cytochrome P450 2D6: Connection with crystallographic and metabolic results.
    Sasahara K; Mashima A; Yoshida T; Chuman H
    Bioorg Med Chem; 2015 Sep; 23(17):5459-65. PubMed ID: 26264841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic drug action: clinical, biochemical, and pharmacological evidence for site specificity of action.
    Borison RL; Hitri A; Blowers AJ; Diamond BI
    Clin Neuropharmacol; 1983 Jun; 6(2):137-50. PubMed ID: 6133618
    [No Abstract]   [Full Text] [Related]  

  • 6. Thioridazine pharmacodynamics: clinical effects may depend upon drug metabolism.
    Lewis MH; Mobilio JN; Rissmiller DJ; Mailman RB
    J Am Osteopath Assoc; 1984 Sep; 84(1 Suppl):124-8. PubMed ID: 6490416
    [No Abstract]   [Full Text] [Related]  

  • 7. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.
    Niedzwiecki DM; Mailman RB; Cubeddu LX
    J Pharmacol Exp Ther; 1984 Mar; 228(3):636-9. PubMed ID: 6707914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study of 2 drugs and a placebo in chronic schizophrenia].
    Tetreault L
    Actual Pharmacol (Paris); 1969; 22():1-18. PubMed ID: 4927120
    [No Abstract]   [Full Text] [Related]  

  • 9. Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors.
    Bylund DB
    J Pharmacol Exp Ther; 1981 Apr; 217(1):81-6. PubMed ID: 6110776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics.
    Vital-Herne J; Gerbino L; Kay SR; Katz IR; Opler LA
    J Clin Psychiatry; 1986 Jul; 47(7):375-9. PubMed ID: 2873133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption and excretion of thioridazine and mesoridazine in man.
    Charalampous KD; Johnson PC; Estevez V
    Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine.
    Kilts CD; Knight DL; Mailman RB; Widerlöv E; Breese GR
    J Pharmacol Exp Ther; 1984 Nov; 231(2):334-42. PubMed ID: 6491985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential effect of noncataleptogenic neuroleptics on mesolimbic dopaminergic function.
    Bartholini G
    Adv Biochem Psychopharmacol; 1977; 16():607-11. PubMed ID: 18902
    [No Abstract]   [Full Text] [Related]  

  • 14. Neuronal basis of neuroleptic-induced extrapyramidal side effects.
    Ossowska K
    Pol J Pharmacol; 2002; 54(4):299-312. PubMed ID: 12523484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic drugs and the dopamine hypothesis.
    Clow A; Jenner P; Theodorou A; Marsden CD
    Lancet; 1979 Apr; 1(8122):934. PubMed ID: 86713
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum.
    Niedzwiecki DM; Cubeddu LX; Mailman RB
    J Pharmacol Exp Ther; 1989 Jul; 250(1):117-25. PubMed ID: 2746491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thioridazine and the neuroleptic radioreceptor assay.
    Mailman RB; Pierce JP; Crofton KM; Petitto J; DeHaven DL; Kilts CD; Lewis MH
    Biol Psychiatry; 1984 Jun; 19(6):833-47. PubMed ID: 6743721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of selective cytochrome P-450 inhibitors on the metabolism of thioridazine. In vitro studies.
    Daniel WA; Syrek M; Haduch A
    Pol J Pharmacol; 1999; 51(5):435-42. PubMed ID: 10817545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.
    Li Z; Ichikawa J; Meltzer HY
    Psychopharmacology (Berl); 2003 May; 167(3):315-23. PubMed ID: 12664192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thioridazine: central dopamine turnover and clinical effects of antipsychotic drugs.
    Bowers MB
    Clin Pharmacol Ther; 1975 Jan; 17(1):73-8. PubMed ID: 1122671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.